Alkermes PLC
Затворен
СекторЗдравеопазване
50.18 4.32
Преглед
Промяна на цената на акция
24 ч
Минимум
47.88
Максимум
51.57
Приходи | -116M -66M |
|---|---|
Продажби | 8.4M 393M |
P/E Средно за сектора | 51.133 50.958 |
EPS | 0.38 |
Марж на печалбата | -16.92 |
Служители | 2,050 |
EBITDA | -98M -22M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +4.01% upside |
Следващи печалби | 28.07.2026 г. |
|---|
Пазарна капитализация | 2B 7.7B |
|---|---|
Предишно отваряне | 45.86 |
Предишно затваряне | 50.18 |
Настроения в новините
By Acuity
10%
90%
13 / 342 Класиране в Healthcare
Alkermes PLC Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
